Vitruvias Therapeutics recalls thyroid tablets as Class I, FDA says

The U.S. Food and Drug Administration listed a Class I recall from Vitruvias Therapeutics Inc. as ongoing in a report dated September 23, 2026. The recall was initiated on August 21, 2026 for a product found to be a superpotent drug.¹

The recalling firm is based at 778 N Dean Rd Ste 600 in Auburn, Alabama.¹ The affected lot is Lot # 504950, with an expiration date of 09/30/2026.¹

The product involved is Thyroid Tablets, USP, 1/2 Grain (30 mg), with each tablet containing levothyroxine (T4) 19 mcg and liothyronine (T3) 4.5 mcg, packaged in bottles of 100 tablets as a prescription-only drug.¹ The product is distributed by Vitruvias Therapeutics of Auburn, AL 36830, is listed as a product of the USA, and carries NDC number 69680-166-00.¹

The recall covers 1955 bottles and was distributed nationwide across the United States.¹ The action was voluntary, initiated by the firm itself.¹

According to the FDA record, the company notified customers by letter, and the FDA's center classified the recall on September 22, 2026.¹ The recall status remains ongoing as of the September 23, 2026 report date, per the agency's enforcement database.